HOME >> BIOLOGY >> NEWS
Anti-HIV drugs save vision, improve outlook for AIDS patients

A new study from Johns Hopkins researchers shows the multiple anti-HIV drug regimen called highly active antiretroviral therapy (HAART) saves eyesight as well as lives. A second study led by Johns Hopkins researchers finds that among AIDS patients with longstanding vision problems, those who took HAART reported higher overall quality of life.

The Johns Hopkins team reported in the April issue of Archives of Ophthalmology that AIDS patients who received HAART had a 75 percent lower risk of visual impairment than those who did not. In the second, multicenter study, published in the May issue of the journal Ophthalmology, AIDS patients with vision loss reported a lower vision-related quality of life, although those who took HAART reported higher overall quality of life than those who did not.

AIDS patients are at high risk of vision loss from cytomegalovirus (CMV) retinitis, an infectious disease of the retina. Symptoms include "floaters" and permanent loss of central vision. With HAART, which became available in 1995, many patients' immune systems seem to recover enough to control CMV retinitis. The condition at one time affected 30 percent of patients at some point during their lives, but has probably decreased to 7.5 percent with the advent of HAART, says John H. Kempen, M.D., Ph.D., lead author of both studies and assistant professor of ophthalmology and epidemiology. By the time CMV is diagnosed, Kempen says, many AIDS patients are already legally blind or have significant vision loss.

"AIDS patients should take HAART as soon as and as much as they can," he says. "HAART often can save both their life and their vision."

In the Archives study, Kempen and his team evaluated 648 AIDS patients seen at the Wilmer Eye Institute at Johns Hopkins between August 1983 and March 2000. Seventeen percent had 20/200 vision (the definition of legal blindness) at the time of diagnosis, while 33 percent had 20/50 vision -- poor eno
'"/>

Contact: Karen Blum
kblum@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
13-May-2003


Page: 1 2 3

Related biology news :

1. Anti-HIV statisticians win $1.125 million NIH Merit Award
2. New Anti-HIV Therapies Needed To Eradicate HIV
3. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
4. New and better drugs for tuberculosis goal of UH professor
5. New technique helps scientists reveal interactions between genes and drugs
6. New database to help develop AIDS drugs
7. Orange, tangerine peels could be better than drugs for lowering cholesterol
8. New papillomavirus target could lead to specific antiviral drugs for precancerous cervical lesions
9. Newer drugs more effective at curing strep throat than penicillin
10. New software developed at Rensselaer predicts promising ingredients for new drugs
11. Protein abundant in human tumors confers resistance to anticancer drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
Breaking Biology Technology:
Cached News: